- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT02980627
iOmit: Reducing Intentional Insulin Misuse in Type 1 Diabetes (iOmit)
Individuals with type 1 diabetes who intentionally omit insulin to lose weight are at high risk for diabetes-related medical complications and premature death. Conventional eating disorder (ED) treatments are not as effective for these patients, suggesting that they need a more tailored treatment approach and one that includes intervention at the time and place when they are making decisions about their diabetes self-management. The goal of treatment development project is to modify an existing mobile application (app) for EDs (Recovery Record; RR) to address the unique needs of adults with type 1 diabetes (T1D) who intentionally omit their insulin for weight control, and test whether app-supported individual treatment decreases eating disorder (ED) symptoms and improves metabolic control. The investigator will also gather preliminary data on the impact of the intervention on health care utilization and costs and calculate attrition to assess feasibility.
The investigators hypothesize that (1) participants will evidence significant decreases in mean blood glucose, (2) participation in routine medical care will increase and emergency visits will decrease, (3) the percentage of time participants are hyperglycemic will decrease, (4) participant scores on the DEPS-R will decrease and (5) participant scores on the EDE will decrease.
연구 개요
상세 설명
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
North Carolina
-
Durham, North Carolina, 미국, 27710
- Duke University Health System
-
Durham, North Carolina, 미국, 27713
- Duke University Medical Center
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Adult aged 18 or older
- Diagnosed with T1D
- Positive for insulin misuse for weight control
- HbA1c ≥ 7.5
- Approved for participation by their physician
- Agrees to continue care with their current physician with consent to contact
- Access to a Smartphone
Exclusion Criteria:
- Non-English speaking
- Cognitive impairments that preclude independent management of T1D
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: Therapy with Mobile App Enhancement
Participants will complete initial assessments and then take part in a 3-month intervention consisting of 12 weekly individual therapy sessions with daily RR app use between sessions.
At the end of the 3-month intervention period, an exit interview will be conducted and participants will complete a second assessment consisting of questionnaires and an ED diagnostic interview, a blood specimen for HbA1c, and 3-days of blinded CGM monitoring.
Participants will then enter a 6-month follow-up period during which time they may continue to use the app, but will no longer attend individual sessions.
Participants will be return to the clinic at 6 and 9 months for follow-up.
|
Treatment includes 12 weekly therapy sessions with daily RR app use between sessions.
Intervention is CBT-based and specifically draws from ACT. ACT is a contextual behavior therapy that emphasizes the function of behavior (e.g., affect regulation) and helps individuals accept (or "tolerate") emotional discomfort for a broader purpose (i.e., personal values).
Broadly, treatment will focus on improving diabetes management by increasing patients' capacity to effectively cope with psychological barriers to self-care using acceptance and mindfulness strategies.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
---|---|
Metabolic Control (Change in HbA1c)
기간: Baseline, 3-months, 6-months and 9-months
|
Baseline, 3-months, 6-months and 9-months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Mobile Technology Engagement (Frequency of Use)
기간: Daily monitoring for 3 months
|
Improvements in metabolic control will correspond with treatment engagement as reflected in frequency of app use from 0-3 months
|
Daily monitoring for 3 months
|
Adequate Insulin Dosing (Frequency)
기간: Baseline, 3-months, 6-months and 9-months
|
Participants will report less frequent under-dosing of insulin
|
Baseline, 3-months, 6-months and 9-months
|
Medical Utilization: Total Number of Primary Care Visits
기간: Baseline, 3-months, 6-months, and 9-months
|
Baseline, 3-months, 6-months, and 9-months
|
|
Medical Utilization: Total Number of Emergency Department Care Visits
기간: Baseline, 3-months, 6-months, and 9-months
|
Baseline, 3-months, 6-months, and 9-months
|
|
Participant Engagement in Treatment as evidenced by attendance/treatment completion
기간: 3 months
|
Attrition will be < 20%
|
3 months
|
Improvement in Metabolic Control; CGM Continuous Glucose Monitoring
기간: Baseline, 3-months
|
Baseline, 3-months
|
|
Decrease in Diabetes-Specific Eating Disorder symptomatology
기간: Baseline, 3-months, 6-months, and 9-months
|
Baseline, 3-months, 6-months, and 9-months
|
|
Decrease in Overall Eating Disorder symptomatology
기간: Baseline, 3-months, 6-months, and 9-months
|
Baseline, 3-months, 6-months, and 9-months
|
공동 작업자 및 조사자
스폰서
수사관
- 수석 연구원: Rhonda Merwin, PhD, Duke University
간행물 및 유용한 링크
일반 간행물
- Merwin RM, Dmitrieva NO, Honeycutt LK, Moskovich AA, Lane JD, Zucker NL, Surwit RS, Feinglos M, Kuo J. Momentary Predictors of Insulin Restriction Among Adults With Type 1 Diabetes and Eating Disorder Symptomatology. Diabetes Care. 2015 Nov;38(11):2025-32. doi: 10.2337/dc15-0753. Epub 2015 Sep 17.
- Merwin RM, Moskovich AA, Dmitrieva NO, Pieper CF, Honeycutt LK, Zucker NL, Surwit RS, Buhi L. Disinhibited eating and weight-related insulin mismanagement among individuals with type 1 diabetes. Appetite. 2014 Oct;81:123-30. doi: 10.1016/j.appet.2014.05.028. Epub 2014 May 29.
- Merwin RM, Moskovich AA, Babyak M, Feinglos M, Honeycutt LK, Mooney J, Freeman SP, Batchelder H, Sangvai D. An open trial of app-assisted acceptance and commitment therapy (iACT) for eating disorders in type 1 diabetes. J Eat Disord. 2021 Jan 6;9(1):6. doi: 10.1186/s40337-020-00357-6.
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- Pro00068040
- 1R21DK106603-01A1 (미국 NIH 보조금/계약)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
1형 당뇨병에 대한 임상 시험
-
Rhythm Pharmaceuticals, Inc.완전한Pro-opiomelanocortin(POMC), Proprotein Convertase Subtilisin/Kexin Type 1(PCSK1) 및 Leptin 수용체(LepR) 유전자 돌연변이미국, 이스라엘, 캐나다, 독일, 그리스, 이탈리아, 포르투갈
Therapy with Mobile App Enhancement에 대한 임상 시험
-
Cochlear모병